This company has been marked as potentially delisted and may not be actively trading.

Cerecor (CERC) Competitors

CERC vs. MANE, KLRA, GMTX, MOR, and ZYME

Should you be buying Cerecor stock or one of its competitors? The main competitors of Cerecor include MANE (MANE), Kailera Therapeutics (KLRA), Gemini Therapeutics (GMTX), MorphoSys (MOR), and Zymeworks (ZYME).

How does Cerecor compare to MANE?

Cerecor (NASDAQ:CERC) and MANE (NYSE:MANE) are both pharmaceutical preparations industry companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

MANE has lower revenue, but higher earnings than Cerecor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerecor	$6.70M	206.49	-$63.50M	-$0.57	N/A
MANE	N/A	N/A	N/A	N/A	N/A

MANE has a net margin of 0.00% compared to Cerecor's net margin of -1,194.82%. MANE's return on equity of 0.00% beat Cerecor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerecor	-1,194.82%	-261.82%	-133.96%
MANE	N/A	N/A	N/A

MANE has a consensus target price of $83.33, indicating a potential downside of 21.36%. Given MANE's stronger consensus rating and higher probable upside, analysts plainly believe MANE is more favorable than Cerecor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerecor	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

62.8% of Cerecor shares are held by institutional investors. 45.7% of Cerecor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, MANE had 4 more articles in the media than Cerecor. MarketBeat recorded 4 mentions for MANE and 0 mentions for Cerecor. MANE's average media sentiment score of 1.62 beat Cerecor's score of 0.16 indicating that MANE is being referred to more favorably in the news media.

Company	Overall Sentiment
Cerecor	Neutral
MANE	Very Positive

Summary

MANE beats Cerecor on 8 of the 11 factors compared between the two stocks.

How does Cerecor compare to Kailera Therapeutics?

Cerecor (NASDAQ:CERC) and Kailera Therapeutics (NASDAQ:KLRA) are both pharmaceutical preparations industry companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

In the previous week, Kailera Therapeutics had 2 more articles in the media than Cerecor. MarketBeat recorded 2 mentions for Kailera Therapeutics and 0 mentions for Cerecor. Cerecor's average media sentiment score of 0.16 beat Kailera Therapeutics' score of 0.00 indicating that Cerecor is being referred to more favorably in the media.

Company	Overall Sentiment
Cerecor	Neutral
Kailera Therapeutics	Neutral

62.8% of Cerecor shares are held by institutional investors. 45.7% of Cerecor shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Kailera Therapeutics has lower revenue, but higher earnings than Cerecor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerecor	$6.70M	206.49	-$63.50M	-$0.57	N/A
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A

Kailera Therapeutics has a net margin of 0.00% compared to Cerecor's net margin of -1,194.82%. Kailera Therapeutics' return on equity of 0.00% beat Cerecor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerecor	-1,194.82%	-261.82%	-133.96%
Kailera Therapeutics	N/A	N/A	N/A

Summary

Cerecor and Kailera Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Cerecor compare to Gemini Therapeutics?

Cerecor (NASDAQ:CERC) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

In the previous week, Gemini Therapeutics had 1 more articles in the media than Cerecor. MarketBeat recorded 1 mentions for Gemini Therapeutics and 0 mentions for Cerecor. Cerecor's average media sentiment score of 0.16 beat Gemini Therapeutics' score of 0.00 indicating that Cerecor is being referred to more favorably in the media.

Company	Overall Sentiment
Cerecor	Neutral
Gemini Therapeutics	Neutral

62.8% of Cerecor shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 45.7% of Cerecor shares are held by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cerecor has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Cerecor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerecor	$6.70M	206.49	-$63.50M	-$0.57	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Gemini Therapeutics has a net margin of 0.00% compared to Cerecor's net margin of -1,194.82%. Gemini Therapeutics' return on equity of -38.78% beat Cerecor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerecor	-1,194.82%	-261.82%	-133.96%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Cerecor has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500.

Summary

Cerecor beats Gemini Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Cerecor compare to MorphoSys?

Cerecor (NASDAQ:CERC) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

In the previous week, Cerecor's average media sentiment score of 0.16 beat MorphoSys' score of 0.00 indicating that Cerecor is being referred to more favorably in the media.

Company	Overall Sentiment
Cerecor	Neutral
MorphoSys	Neutral

Cerecor has higher earnings, but lower revenue than MorphoSys. Cerecor is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerecor	$6.70M	206.49	-$63.50M	-$0.57	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

62.8% of Cerecor shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 45.7% of Cerecor shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MorphoSys has a net margin of -226.79% compared to Cerecor's net margin of -1,194.82%. Cerecor's return on equity of -261.82% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerecor	-1,194.82%	-261.82%	-133.96%
MorphoSys	-226.79%	-694.31%	-22.55%

Cerecor has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Summary

Cerecor beats MorphoSys on 8 of the 12 factors compared between the two stocks.

How does Cerecor compare to Zymeworks?

Zymeworks (NASDAQ:ZYME) and Cerecor (NASDAQ:CERC) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

In the previous week, Zymeworks had 10 more articles in the media than Cerecor. MarketBeat recorded 10 mentions for Zymeworks and 0 mentions for Cerecor. Cerecor's average media sentiment score of 0.16 beat Zymeworks' score of -0.20 indicating that Cerecor is being referred to more favorably in the news media.

Company	Overall Sentiment
Zymeworks	Neutral
Cerecor	Neutral

Zymeworks currently has a consensus target price of $38.00, indicating a potential upside of 59.06%. Given Zymeworks' stronger consensus rating and higher probable upside, equities analysts clearly believe Zymeworks is more favorable than Cerecor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92
Cerecor	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cerecor has lower revenue, but higher earnings than Zymeworks. Cerecor is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.97M	16.63	-$81.13M	-$1.08	N/A
Cerecor	$6.70M	206.49	-$63.50M	-$0.57	N/A

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 62.8% of Cerecor shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by insiders. Comparatively, 45.7% of Cerecor shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Zymeworks has a net margin of -76.56% compared to Cerecor's net margin of -1,194.82%. Zymeworks' return on equity of -26.00% beat Cerecor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-76.56%	-26.00%	-20.57%
Cerecor	-1,194.82%	-261.82%	-133.96%

Zymeworks has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Cerecor has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Summary

Zymeworks beats Cerecor on 11 of the 17 factors compared between the two stocks.

Get Cerecor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CERC vs. The Competition

Export

Metric	Cerecor	Pharmaceutical Preparations Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.38B	$897.33M	$6.18B	$12.24B
Dividend Yield	N/A	4.84%	2.78%	5.24%
P/E Ratio	-25.28	1.71	28.73	27.26
Price / Sales	206.49	122.44	507.60	64.06
Price / Cash	N/A	20.07	43.30	53.97
Price / Book	65.50	7.71	10.00	6.83
Net Income	-$63.50M	-$5.06M	$3.54B	$332.87M

Cerecor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CERC Cerecor	N/A	$14.41 -9.5%	N/A	+201.5%	$1.38B	$6.70M	N/A	31	Gap Up
MANE MANE	N/A	$98.23 -7.8%	$83.33 -15.2%	N/A	$3.67B	N/A	N/A	19	High Trading Volume
KLRA Kailera Therapeutics	N/A	$25.00 +1.0%	N/A	N/A	$3.09B	N/A	N/A	145
GMTX Gemini Therapeutics	N/A	$67.26 -2.3%	N/A	+61.2%	$2.91B	N/A	N/A	30
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CERC) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cerecor (CERC) Competitors